RavenConnects

Novotech is the leading Asia-Pacific biotech CRO. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 pre-clinical and clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. Novotech has over 2500 staff working across our offices in 13 geographies.

Novotech

Pharma Intelligence UK Ltd

From biomarkers to regulatory compliance, and the impact of AI/ML

The field of precision medicine is rapidly evolving, enabling the development of innovative therapies highly tailored to individuals’ genetic profiles - resulting in revolutionized treatments and improved patient outcomes. Discover expert insights on the current landscape of personalized medicine, including the opportunities and challenges, including:

Report Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

CGTs: Transforming the treatment landscape to address unmet needs

Access this insightful white paper to:

Whitepaper Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Innovative and evolving therapeutic strategies for DLBCL

Access this in-depth report to:

Report Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Combating a wide range of diseases with RNA Therapies

In this latest white paper, global leading CRO, Novotech, explores the latest advancements, trends and challenges in global RNA research. Access it now to gain insights and key statistics on:

Whitepaper Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Advances and opportunities in Liver Cancer research

Liver cancer is one of the leading causes of cancer death, with new cases predicted to rise by an alarming 70% by the time we reach 2025 (vs. 2022). Hepatocellular carcinoma, or HCC, accounts for 90% of cases, and poses significant challenges in treatment. Access this in-depth report to explore the global drug development landscape, and how promising advances in treatments are providing hope for the future. Explore topics including:

Report Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Radiopharmaceuticals: Global Clinical Trial Landscape (2024)

Established originally from radiation therapy, radiopharmaceuticals have made significant development progress in recent years. In 2018, the FDA approved Lutathera for neuroendocrine tumors, signifying a new hope in the treatment of solid tumors. As the global clinical trial landscape continues to evolve, this white paper explores:

Whitepaper Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

New EU Clinical Trial Regulations

Explore the challenges and benefits for biotechs conducting trials in the EU, and why partnerships are crucial to support the trial journey, as they discuss:

Report Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Antibody-Drug Conjugates: Global Clinical Trial Landscape (2024)

Don’t miss critical data and informative market analysis that examines ADC’s current state, development trends, and future potential. This data-rich report features:

Report Clinical Studies Pharmaceutical Research and Development

Novotech

Pharma Intelligence UK Ltd

Oesophageal Cancer: Global Clinical Trial Landscape (2024)

Discover more about this disease and the critical clinical research being conducted to combat and treat it, in this data-packed report. Download the report now to explore:

Report Clinical Studies Pharmaceutical Research and Development